The Ahmedabad-based Zydus Cadila Healthcare announced a strategic alliance with Mumbai-based Kopran for marketing and manufacturing of formulation
The Ahmedabad-based Zydus Cadila Healthcare announced a strategic alliance with Mumbai-based Kopran for marketing and manufacturing of formulation brands and collaborative research while taking over the Kopran's anti-hypertensive drug 'Aten' for Rs. 75 crores. Aten (Atenolol), is the largest brand in the cardiovascular segment. Aten, today, ranks within the top 50 Indian Pharma brands.
As a part of the alliance, the Mumbai-based Kopran has perpetually assigned its anti-hypertensive drug 'Aten'(Atenol) to Zydus Cadila for a consideration of Rs. 75 crores but will continue to manufacture the drug at its facility, Zydus Cadila release said here. Zydus has also entered into a seperate technology transfer agreement with Kopran for zero impurity Atenol which includes milestone payments totalling Rs. 20 crores."We saw Aten as a good fit in terms of its size and presence in the cardiac care market," Mr.Pankaj, Managing Director, Zydus Cadila said. Mr.Surendra Somani, MD, Kopran said, "while Aten would grow faster in the hands of Zydus, Kopran would be able to acheive higher growths through its strategy of launching new products."
Kopran will also co-market Zydus Cadila's new products in diabetes, central nervous system and other speciality segments including brands Olanzapine(Olzep), Zolipidem(Zopiz) and anti-diabetic Glimepiride(Gliran).
Zydus Cadila has been leveraging its strength in new product development to introduce several new products, many of them for the first time in India. While on one hand Aten would grow faster in the hands of Zydus Cadila, Kopran would be able to achieve higher growths through its strategy of launching new products.
